TCR repertoire analysis reveals that the tumor recognizing T cells were limited to merely 10% of intratumoral CD8+ T cells.405 ICB can robustly reinvigorate Tex cell function, making it one of the most promising cancer therapies in the clinic.406–408 Antibodies targeting IRs on tumor-infiltrating T cells, such as PD-1/PD-L1 (among others), have been demonstrated impressive clinical activities across a variety of cancer types. This evidence concerns the gene PDCD1 and cancer.